Aerovate Therapeutics, Inc. (AVTE)

USD 2.53

(-1.17%)

Annual Income Statements

(In USD)
Breakdown 2023 2022 2021 2020 2019
Revenue - - - - -
Cost of Revenue 96 Thousand 68 Thousand 15 Thousand 1000.00 -
Gross Profit -96 Thousand -68 Thousand -15 Thousand -1000.00 -
Operating Expenses 81.4 Million 53.23 Million 23.02 Million 8.88 Million 3.33 Million
Selling, General and Administrative Expenses 17.19 Million 14.61 Million 8.03 Million 949 Thousand 218 Thousand
Research and Development Expenses 64.21 Million 38.62 Million 14.98 Million 7.94 Million 3.11 Million
Other Expenses - -79 Thousand -3000.00 -647 Thousand 1000.00
Cost and Expenses 81.4 Million 53.23 Million 23.02 Million 8.88 Million 3.33 Million
Operating Income -81.4 Million -53.23 Million -23.02 Million -8.88 Million -3.33 Million
Interest Expense - - 65 Thousand 75 Thousand -
Income Tax Expense 56 Thousand 25 Thousand 3000.00 -572 Thousand 1000.00
Earnings before Tax -75.46 Million -51.48 Million -22.96 Million -9.61 Million -3.33 Million
Net Income -75.52 Million -51.51 Million -22.96 Million -9.03 Million -3.33 Million
Earnings Per Share Basic -2.87 -2.10 -0.94 -0.37 -0.14
Earnings Per Share Diluted -2.87 -2.10 -0.94 -0.37 -0.14
Weighted Average Shares Outstanding 26.33 Million 24.47 Million 24.41 Million 24.41 Million 24.41 Million
Weighted Average Shares Outstanding (Diluted) 26.33 Million 24.47 Million 24.41 Million 24.41 Million 24.41 Million
Gross Margin - - - - -
EBIT Margin - - - - -
Profit Margin - - - - -
EBITDA -81.31 Million -53.16 Million -23 Million -8.88 Million 1000.00
Earnings Before Tax Margin - - - - -

Income Statement Charts